Anteris Technologies Ltd represents values of exceptional innovation, integrity, and commitment to advancing healthcare solutions. With a strong corporate philosophy focused on revolutionizing regenerative medicine, Anteris Technologies is dedicated to improving patient outcomes through its cutting-edge technologies and therapeutic products. The company's unwavering dedication to research and development, combined with a patient-centric approach, ensures the delivery of high-quality and effective medical solutions. Anteris Technologies Ltd strives to be at the forefront of the industry, continuously pushing boundaries and offering groundbreaking advancements in regenerative medicine.

Anteris Technologies Ltd is primarily present in Australia.

Anteris Technologies Ltd has achieved several significant milestones. Notably, the company successfully completed the first-in-human implantation of its DurAVR™ aortic valve, demonstrating its commitment to revolutionizing cardiac surgery. Furthermore, Anteris Technologies received regulatory approval for DurAVR™ in Europe, marking a major step forward in expanding its market reach. The company also forged strategic collaborations with renowned medical institutions, enhancing its research and development capabilities. Anteris Technologies is continuously exploring opportunities for advancements in cardiovascular technologies and aims to provide innovative solutions to improve patient outcomes.

Anteris Technologies Ltd is a leading biotechnology company headquartered in Australia. Founded in 2003, the company focuses on developing and commercializing cutting-edge medical devices and regenerative therapeutics. Anteris Technologies is dedicated to advancing healthcare through innovative solutions that address unmet medical needs across various therapeutic areas. With a team of highly skilled scientists, researchers, and engineers, the company has successfully developed groundbreaking products that have the potential to revolutionize patient care. Anteris Technologies Ltd remains committed to continuous innovation and playing a significant role in shaping the future of the biotechnology industry.

The main competitors of Anteris Technologies Ltd in the market include companies like Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, and Abbott Laboratories.

Anteris Technologies Ltd is primarily active in the medical and healthcare industries.

The business model of Anteris Technologies Ltd focuses on the development and commercialization of innovative medical technologies. As a leading provider in the healthcare industry, Anteris Technologies specializes in the design and production of advanced biomedical products aimed at enhancing patients' quality of life. With a strong emphasis on research and development, the company continuously strives to introduce groundbreaking solutions for various medical conditions. Anteris Technologies is committed to bringing revolutionary therapies and medical devices to market, ensuring better treatment options and improved outcomes for patients worldwide.

Anteris Technologies Global KGV ir -1,77.

Anteris Technologies Global KUV ir 32,59.

AlleAktien kvalitātes vērtējums Anteris Technologies Global ir 2/10.

gaidāmā Anteris Technologies Global apgrozījums ir 3,71 milj. USD.

gaidāmā Anteris Technologies Global peļņa ir -68,36 milj. USD.

Anteris Technologies Ltd is a company specialized in medical technology. The company's business model is based on the development and commercialization of innovative products focused on the treatment of heart and vascular diseases. The company is divided into three main areas: 1. Heart valve and stent technology: Anteris Technologies develops innovative heart valve and stent technologies that enable improved treatment for patients with heart and vascular diseases. These products offer higher performance, better adaptability to the patient's anatomical conditions, and increased compatibility. 2. Closure and implant systems: Anteris Technologies has also developed closure and implant systems that enable effective treatment for patients with vascular diseases. These products are capable of opening blocked or damaged blood vessels and improving blood flow. 3. Research and development: Anteris Technologies also invests in research and development to drive the development of innovative technologies. Through collaboration with leading research institutions and clinical partners, the company can develop and bring new solutions in medical technology to the market. Anteris Technologies' products are designed for a wide range of applications and can be used to treat various medical issues. These include coronary artery disease, aortic valve disease, heart valve disease, and peripheral arterial occlusive disease. The company distributes its products through a network of distribution partners and medical professionals. Sales and marketing are conducted by an experienced team of professionals with extensive experience in the medical technology industry. Anteris Technologies also aims to work closely with medical professionals to develop innovative solutions and constantly improve its products. To achieve this, the company collaborates closely with a variety of partners, including doctors, hospitals, and research institutes. In recent years, the company has experienced strong growth and has been able to establish a strong presence in the global market. This was facilitated by the introduction of innovative products that enable effective and safe treatment of heart and vascular diseases. Overall, Anteris Technologies has developed a strong business model based on the development of innovative medical technology products and collaboration with leading medical professionals. The company continues to strive to advance the development of new innovative products and improve medical care worldwide.

Anteris Technologies Global izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Anteris Technologies Global vai uzņēmums nedod dividendes.

Anteris Technologies Global ISIN ir AU0000088841.

Anteris Technologies Global simbols ir AVR.AX.

Pēdējo 12 mēnešu laikā Anteris Technologies Global maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Anteris Technologies Global plāno maksāt dividendes 0 USD apmērā.

Anteris Technologies Global pašreizējā dividendu rentabilitāte ir .

Anteris Technologies Global maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Anteris Technologies Global pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Anteris Technologies Global tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Anteris Technologies Global apmērā 0 USD, kas tika izmaksāta 2.08.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 2.08.2025..

Pēdējās dividendes izmaksa notika 2.08.2025..

Gadā 2024, Anteris Technologies Global izmaksāja 0 USD dividendes.

Anteris Technologies Global dividendes tiek izmaksātas USD.